Professor William Sievert - Researcher Profile

We do not have a photograph of this person yet.

Address

Faculty of Medicine, Nursing & Health Sciences
Monash University, Clayton

Biography

Professor William Sievert is a clinician-scientist with dual appointments at Monash University and Monash Health as the Director of the Gastrointestinal and Liver Unit. Professor Sievert has a long-term interest in liver disease and directs an active clinical research unit comprising physician-scientists, clinical research nurses and research students.

The Clinical Research Unit has been continuously active over ten years and regularly contributes to international trials of new antiviral agents for hepatitis B and C in addition to developing and leading national investigator-initiated studies. He also directs a basic research laboratory investigating mechanisms of inflammatory liver injury and hepatic fibrogenesis, with a translational focus on identification and development of potential hepatic antifibrotic agents.

Professor Sievert is also active in medical education including the development of new undergraduate and graduate medical curricula at Monash University.

Qualifications

FELLOW
Institution: Royal Australasian College of Physicians
Year awarded: 1990
GASTROENTEROLOGY
Institution: American Board of Internal Medicine
Year awarded: 1986
INTERNAL MEDICINE
Institution: American Board of Internal Medicine
Year awarded: 1983
MEDICINE
Institution: Texas Tech University School of Medicine
Year awarded: 1980

Publications

Journal Articles

Kao, J., Jensen, D.M., Manns, M.P., Jacobson, I.M., Kumada, H., Toyota, J., Heo, J., Yoffe, B., Sievert, W., Fernando, B., Peng, C., Roberts, S.K., Lee, Y., Bhore, R., Mendez, P., Hughes, E.A., Noviello, S., 2016, Daclatasvir plus asunaprevir for HCV genotype 1b infection in patients with or without compensated cirrhosis: A pooled analysis, Liver International [P], Wiley-Blackwell Publishing Ltd., United Kingdom.

Bennett, H., Waser, N., Johnston, K., Kao, J., Lim, Y., Duan, Z., Lee, Y., Wei, L., Chen, C., Sievert, W., Yuan, Y., Li, H., 2015, A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan, Hepatology International [P], vol 9, issue 3, Springer (India) Private Ltd, India, pp. 378-390.

Hezode, C., Hirschfield, G.M., Ghesquiere, W.G., Sievert, W., Rodriguez-Torres, M., Shafran, S.D., Thuluvath, P.J., Tatum, H.A., Waked, I.A., Esmat, G., Lawitz, E., Rustgi, V.K., Pol, S.B., Weis, N., Pockros, P.J., Bourliere, M., Serfaty, L., Vierling, J.M., Fried, M.W., Weiland, O., Brunetto, M.R., Everson, G.T., Zeuzem, S., Kwo, P.Y., Sulkowski, M.S., Brau, N., Hernandez, D., McPhee, F., Wind-Rotolo, M., Liu, Z., Noviello, S., Hughes, E.A., Yin, P.D., Schnittman, S., 2015, Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study, Gut [P], vol 64, issue 6, B M J Group, United Kingdom, pp. 948-956.

Lawitz, E., Gane, E.J., Pearlman, B., Tam, E., Ghesquiere, W., Guyader, D., Alric, L., Bronowicki, J., Lester, L., Sievert, W., Ghalib, R., Balart, L., Sund, F., Lagging, M., Dutko, F., Shaughnessy, M., Hwang, P., Howe, A.Y.M., Wahl, J., Robertson, M.N., Barr, E., Haber, B., 2015, Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with prev, Lancet [P], vol 385, issue 9973, The Lancet Publishing Group, London United Kingdom, pp. 1075-1086.

Poordad, F., Sievert, W., Mollison, L., Bennett, M., Tse, E., Brau, N., Levin, J.M., Sepe, T.E., Lee, S.S., Angus, P.W., Conway, B., Pol, S.B., Boyer, N., Bronowicki, J., Jacobson, I.M., Muir, A.J., Reddy, K.R., Tam, E., Ortiz-Lasanta, G., de Ledinghen, V., Sulkowski, M.S., Boparai, N., McPhee, F., Hughes, E.A., Swenson, E., Yin, P.D., 2015, Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection, Jama-Journal of the American Medical Association [P], vol 313, issue 17, American Medical Association, United States, pp. 1728-1735.

Sievert, W., 2015, HCV-infected patients need access now to new direct-acting antiviral agents to avert liver-related deaths, Medical Journal of Australia [P], vol 202, issue 9, Australasian Medical Publishing Company Pty. Ltd., Strawberry Hills, NSW 2012 Australia, p. 479.

Holmes, J.A., Congiu, M., Bonanzinga, S., Sandhu, M.K., Kia, Y., Bell, S.J., Nguyen, T., Iser, D.M., Visvanathan, K., Sievert, W., Bowden, D.S., Desmond, P.V., Thompson, A.J.V., 2015, The relationships between IFNL4 genotype, intrahepatic interferon-stimulated gene expression and interferon treatment response differs in HCV-1 compared with HCV-3, Alimentary Pharmacology and Therapeutics [P], vol 42, issue 3, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 296-306.

Manns, M.P., Pol, S.B., Jacobson, I.M., Marcellin, P.M., Gordon, S.C., Peng, C., Chang, T., Everson, G.T., Heo, J., Gerken, G., Yoffe, B., Towner, W.J., Bourliere, M., Metivier, S., Chu, C., Sievert, W., Bronowicki, J., Thabut, D., Lee, Y., Kao, J., McPhee, F., Kopit, J., Mendez, P., Linaberry, M., Hughes, E.A., Noviello, S., 2014, All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study, Lancet [P], vol 384, issue 9954, The Lancet Publishing Group, United Kingdom, pp. 1597-1605.

Roberts, S.K., Mitchell, J., Leung, R., Booth, D., Bollipo, S., Ostapowicz, G., Sloss, A., McCaughan, G., Dore, G., Thompson, A.J.V., Crawford, D., Sievert, W., Weltman, M.D., Cheng, W., George, J., 2014, Distribution of interferon lambda-3 gene polymorphisms in Australian patients with previously untreated genotype 1 chronic hepatitis C: analysis from the PREDICT and CHARIOT studies, Journal Of Gastroenterology And Hepatology [P], vol 29, issue 1, Wiley-Blackwell Publishing Asia, Australia, pp. 179-184.

Sievert, W., Razavi, H.A., Estes, C., Thompson, A.J.V., Zekry, A., Roberts, S.K., Dore, G., 2014, Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia, Journal Of Gastroenterology And Hepatology [P], vol 29, issue Suppl 1, Wiley-Blackwell Publishing Asia, Australia, pp. 1-9.

Parker, C., Tong, S.Y.C., Dempsey, K., Condon, J., Sharma, S.K., Chen, J.W.C., Sievert, W., Davis, J.S., 2014, Hepatocellular carcinoma in Australia's Northern Territory: high incidence and poor outcome, Medical Journal Of Australia [P], vol 201, issue 8, Australasian Medical Publishing Company Pty Ltd, Australia, pp. 470-474.

Bruggmann, P., Berg, T., Ovrehus, A.L.H., Moreno, C.A., Brandao-Mello, C.E., Roudot-Thoraval, F., Marinho, R.T., Sherman, M., Ryder, S.D., Sperl, J., Akarca, U.S., Balik, I., Bihl, F.K., Bilodeau, M., Blasco, A.J., Buti, M.A., Calinas, F., Calleja, J.L., Cheinquer, H., Christensen, P.B., Clausen, M., Coelho, H.S.M., Cornberg, M., Cramp, M.E., Dore, G., Doss, W.H., Duberg, A.S., El-Sayed, M.H., Ergor, G., Esmat, G., Estes, C., Falconer, K., Felix, J., Ferraz, M.L.G., Ferreira, P.R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J.A., Goncales, F.L., Gower, E.E., Gschwantler, M., Guimaraes Pessoa, M., Hezode, C., Hofer, H., Husa, P., Idilman, R., Kaberg, M., Kaita, K., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W.J., Lavanchy, D., Lazaro, P., Marotta, P., Mauss, S., Mendes-Correa, M.C.J., Mullhaupt, B., Myers, R.P., Negro, F., Nemecek, V., Ormeci, N., Parkes, J., Peltekian, K.M., Ramji, A.S., Razavi, H.A., Reis, N., Roberts, S.K., Rosenberg, W.M.C., Sarmento-Castro, R., Sarrazin, C.M., Semela, D., Shiha, G.E., Sievert, W., Starkel, P., Stauber, R.E., Thompson, A.J.V., Urbanek, P., Van Thiel, I., Van Vlierberghe, H., Vandijck, D.M., Vogel, W., Waked, I.A., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., Hindman, S.J., 2014, Historical epidemiology of hepatitis C virus (HCV) in selected countries, Journal Of Viral Hepatitis [P], vol 21, issue Supplement S1, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 5-33.

Holmes, J.A., Roberts, S.K., Ali, R.J., Dore, G., Sievert, W., McCaughan, G., Crawford, D., Cheng, W., Weltman, M.D., Bonanzinga, S., Visvanathan, K., Sundararajan, V., Desmond, P.V., Bowden, D.S., Matthews, G.V., Thompson, A., 2014, ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response, Hepatology [P], vol 59, issue 6, John Wiley & Sons, United States, pp. 2152-2160.

Kitson, M.T., George, J., Dore, G., Leung, R., Button, P., McCaughan, G., Crawford, D., Sievert, W., Weltman, M.D., Cheng, W., Roberts, S.K., 2014, Interleukin-28B rs12979860 C allele: protective against advanced fibrosis in chronic hepatitis C genotype 1 infection, Journal Of Gastroenterology And Hepatology [P], vol 29, issue 7, Wiley-Blackwell Publishing Asia, Australia, pp. 1458-1462.

Hodge, A., Lourensz, D., Vaghjiani, V., Nguyen, K.H., Tchongue, J., Wang, B., Murthi, P., Sievert, W., Manuelpillai, U.C., 2014, Soluble factors derived from human amniotic epithelial cells suppress collagen production in human hepatic stellate cells, Cytotherapy [P], vol 16, issue 8, Elsevier Ltd, United Kingdom, pp. 1132-1144.

Wedemeyer, H., Duberg, A.S., Buti, M.A., Rosenberg, W.M.C., Frankova, S., Esmat, G., Ormeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U.S., Aleman, S., Balik, I., Berg, T., Bihl, F.K., Bilodeau, M., Blasco, A.J., Brandao-Mello, C.E., Bruggmann, P., Calinas, F., Calleja, J.L., Cheinquer, H., Christensen, P.B., Clausen, M., Coelho, H.S.M., Cornberg, M., Cramp, M.E., Dore, G., Doss, W.H., El-Sayed, M.H., Ergor, G., Estes, C., Falconer, K., Felix, J., Ferraz, M.L.G., Ferreira, P.R., Garcia-Samaniego, J., Gerstoft, J., Giria, J.A., Goncales, F.L., Guimaraes Pessoa, M., Hezode, C., Hindman, S.J., Hofer, H., Husa, P., Idilman, R., Kaberg, M., Kaita, K., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W.J., Lavanchy, D., Lazaro, P., Marinho, R.T., Marotta, P., Mauss, S., Mendes-Correa, M.C.J., Moreno, C.A., Mullhaupt, B., Myers, R.P., Nemecek, V., Ovrehus, A.L.H., Parkes, J., Peltekian, K.M., Ramji, A.S., Razavi, H.A., Reis, N., Roberts, S.K., Roudot-Thoraval, F., Ryder, S.D., Sarmento-Castro, R., Sarrazin, C.M., Semela, D., Sherman, M., Shiha, G.E., Sperl, J., Starkel, P., Stauber, R.E., Thompson, A.J.V., Urbanek, P., Van Damme, P., Van Thiel, I., Vandijck, D.M., Vogel, W., Waked, I.A., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., Gower, E.E., 2014, Strategies to manage hepatitis C virus (HCV) disease burden, Journal Of Viral Hepatitis [P], vol 21, issue Supplement S1, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 60-89.

Buti, M., Agarwal, K., Horsmans, Y., Sievert, W., Janczewska, E., Zeuzem, S., Nyberg, L.M., Brown Jr, R.S., Hezode, C., Rizzetto, M., Parana, R., De Meyer, S., De Masi, R.J., Luo, D., Bertelsen, K., Witek, J., 2014, Telaprevir twice daily is noninferior to telaprevir every 8 hours for patients with chronic hepatitis C, Gastroenterology [P], vol 146, issue 3, W.B. Saunders Co., United States, pp. 744-753 e3.

Razavi, H.A., Waked, I.A., Sarrazin, C.M., Myers, R.P., Idilman, R., Calinas, F., Vogel, W., Mendes-Correa, M.C.J., Hezode, C., Lazaro, P., Akarca, U.S., Aleman, S., Balik, I., Berg, T., Bihl, F.K., Bilodeau, M., Blasco, A.J., Brandao-Mello, C.E., Bruggmann, P., Buti, M.A., Calleja, J.L., Cheinquer, H., Christensen, P.B., Clausen, M., Coelho, H.S.M., Cramp, M.E., Dore, G., Doss, W.H., Duberg, A.S., El-Sayed, M.H., Ergor, G., Esmat, G., Falconer, K., Felix, J., Ferraz, M.L.G., Ferreira, P.R., Frankova, S., Garcia-Samaniego, J., Gerstoft, J., Giria, J.A., Goncales, F.L., Gower, E.E., Gschwantler, M., Guimaraes Pessoa, M., Hindman, S.J., Hofer, H., Husa, P., Kaberg, M., Kaita, K., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W.J., Lavanchy, D., Marinho, R.T., Marotta, P., Mauss, S., Moreno, C.A., Murphy, K., Negro, F., Nemecek, V., Ormeci, N., Ovrehus, A.L.H., Parkes, J., Pasini, K., Peltekian, K.M., Ramji, A.S., Reis, N., Roberts, S.K., Rosenberg, W.M.C., Roudot-Thoraval, F., Ryder, S.D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G.E., Sievert, W., Sperl, J., Starkel, P., Stauber, R.E., Thompson, A.J.V., Urbanek, P., Van Damme, P., Van Thiel, I., Van Vlierberghe, H., Vandijck, D.M., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Mullhaupt, B., Estes, C., 2014, The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm, Journal Of Viral Hepatitis [P], vol 21, issue Supplement S1, Wiley-Blackwell Publishing Ltd, United Kingdom, pp. 34-59.

Vaghjiani, V., Vaithilingam, V., Tuch, B., Sievert, W., Manuelpillai, U.C., 2013, Deriving hepatocyte-like cells from placental cells for transplantation, Current Stem Cell Research and Therapy [P], vol 8, issue 1, Bentham Science Publishers, Netherlands, pp. 15-24.

Holmes, J., Nguyen, T., Ratnam, D., Heerasing, N.M., Tehan, J.V., Bonanzinga, S., Dev, A.T., Bell, S., Pianko, S., Chen, R., Visvanathan, K., Hammond, R.A., Iser, D., Rusli, F., Sievert, W., Bowden, S., Thompson, A.J., 2013, IL28B genotype is not useful for predicting treatment outcome in Asian chronic hepatitis B patients treated with pegylated interferon-alpha, Journal Of Gastroenterology And Hepatology [P], vol 28, issue 5, Wiley-Blackwell, Australia, pp. 861-866.

Sievert, W., Macrae, F.A., Leggett, B., 2013, Investigating iron deficiency anaemia, Medical Journal Of Australia [P], vol 198, issue 10, Australasian Medical Publishing Company Pty Ltd, Australia, p. 563.

Allison, C.C., Ferrand, J.F.P., McLeod, L., Hassan, M., Kaparakis-Liaskos, M., Grubman, A., Bhathal, P.S., Dev, A.T., Sievert, W., Jenkins, B.J., Ferrero, R.L., 2013, Nucleotide oligomerization domain 1 enhances IFN-gamma signaling in gastric epithelial cells during Helicobacter pylori infection and exacerbates disease severity, Journal Of Immunology [P], vol 190, issue 7, American Association of Immunologists, United States, pp. 3706-3715.

Marcellin, P., Gane, E.J., Buti, M., Afdhal, N.H., Sievert, W., Jacobson, I.M., Washington, M.K., Germanidis, G., Flaherty, J.F., Schall, R.A., Bornstein, J.D., Kitrinos, K.M., Subramanian, G.M., McHutchison, J.G., Heathcote, E., 2013, Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study, Lancet [P], vol 381, issue 9865, Lancet Publishing Group, United Kingdom, pp. 468-475.

Kitson, M., Dore, G., George, J., McCaughan, G., Crawford, D., Sievert, W., Weltman, M.D., Cheng, W., Roberts, S.K., 2013, Vitamin D status does not predict sustained virologic response or fibrosis stage in chronic hepatitis C genotype 1 infection, Journal Of Hepatology [P], vol 58, issue 3, Elsevier, Netherlands, pp. 467-472.

Gellad, Z.F., Muir, A.J., McHutchison, J.G., Sievert, W., Sharara, A.I., Brown, K.A., Flisiak, R., Jacobson, I.M., Kershenobich, D., Manns, M.P., Schulman, K., Reed, S.D., 2012, Cost-effectiveness of truncated therapy for hepatitis C based on rapid virologic response, Value In Health [P], vol 15, issue 6, Elsevier, United States, pp. 876-886.

Crawford, D., Dore, G., Sievert, W., Cheng, W., Weltman, M.D., McCaughan, G., Rawlinson, W., Marks, P., Yoshihara, M., Rizkalla, B., Roberts, S.K., 2012, Early on-treatment viral load and baseline METAVIR score: improved prediction of sustained virological response in HCV genotype 1 patients, Antiviral Therapy [P], vol 17, issue 5, International Medical Press, United Kingdom, pp. 849-854.

Ratnam, D., Dev, A.T., Nguyen, T., Sundararajan, V., Harley, H., Cheng, W., Lee, A., Rusli, F., Chen, R., Bell, S., Pianko, S., Sievert, W., 2012, Efficacy and tolerability of pegylated interferon-alpha-2a in chronic hepatitis B: a multicenter clinical experience, Journal Of Gastroenterology And Hepatology [P], vol 27, issue 9, Wiley-Blackwell, Australia, pp. 1447-1453.

Lok, A.S., Trinh, H., Carosi, G., Akarca, U.S., Gadano, A., Habersetzer, F., Sievert, W., Wong, D., Lovegren, M., Cohen, D., Llamoso, C., 2012, Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-naive patients with chronic hepatitis B, Gastroenterology [P], vol 143, issue 3 (Art. ID: e1), W.B. Saunders, United States, pp. 619-628.

Manuelpillai, U.C., Lourensz, D., Vaghjiani, V., Tchongue, J., Lacey, D., Tee, J.Y., Murthi, P., Chan, M.K.J., Hodge, A., Sievert, W., 2012, Human amniotic epithelial cell transplantation induces markers of alternative macrophage activation and reduces established hepatic fibrosis, PLoS ONE [E], vol 7, issue 6 (Art. No: e38631), Public Library of Science, United States, pp. 1-11.

Manns, M.P., Akarca, U.S., Chang, T., Sievert, W., Yoon, S., Tsai, N., Min, A., Pangerl, A., Beebe, S., Yu, M., Wongcharatrawee, S., 2012, Long-term safety and tolerability of entecavir in patients with chronic hepatitis B in the rollover study ETV-901, Expert Opinion on Drug Safety [P], vol 11, issue 3, Informa Healthcare USA, United Kingdom, pp. 361-368.

Ratnam, D., Sievert, W., Visvanathan, K., 2012, Natural killer cells display impaired responses to toll like receptor 9 that support viral persistence in chronic hepatitis B, Cellular Immunology [P], vol 279, issue 1, Academic Press, United States, pp. 109-115.

Sievert, W., 2012, Preventing severe chemotherapy-induced reactivation of hepatitis B - Time to adopt a universal approach, Current Hepatitis Reports [P], vol 11, issue 4, Springer Healthcare, United States, pp. 195-196.

Knight, V., Tchongue, J., Dowling, D., Tipping, P., Sievert, W., 2012, Protease-activated receptor 2 promotes experimental liver fibrosis in mice and activates human hepatic stellate cells, Hepatology [P], vol 55, issue 3, John Wiley & Sons, United States, pp. 879-887.

Tye, Y.M.H., Kennedy, C.L., Najdovska, M., McLeod, L., McCormack, W., Hughes, N.R., Dev, A.T., Sievert, W., Ooi, C., Ishikawa, T., Oshima, H., Bhathal, P.S., Parker, A.E., Oshima, M., Tan, P., Jenkins, B.J., 2012, STAT3-driven upregulation of TLR2 promotes gastric tumorigenesis independent of tumor inflammation, Cancer Cell [P], vol 22, issue 4, Cell Press, United States, pp. 466-478.

Postgraduate Research Supervisions

Current Supervision

Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
How human amnion epithelial cells alter hepatic stellate cells and macrophages to resolve hepatic fibrosis.
Supervisors:
Sievert, W (Main), Lim, R (Associate).
Program of Study:
(DOCTORATE BY RESEARCH).
Thesis Title:
Human amniotic cell therapy and their soluble factors in Gastrointestinal and Hepatic Disorders.
Supervisors:
Sievert, W (Main), Moore, G (Associate).

Completed Supervision

Student:
Browning, A.
Program of Study:
A role for the inflammasome in STAT3-mediated gastric tumourigenesis. (PHD) 2015.
Supervisors:
Jenkins, B (Main), Sievert, W (Associate).
Student:
Dev, A.
Program of Study:
FACTORS EFFECTING THE EPIDEMIOLOGY AND TREATMENT OF HEPATITIS C IN SOUTHEAST ASIANS. (PHD) 2003.
Supervisors:
Sievert, W (Main), Holdsworth, S (Associate).
Student:
Hodge, A.
Program of Study:
Novel therapies in chronic liver disease. (PHD) 2014.
Supervisors:
Sievert, W (Main), Moore, G (Associate).
Student:
Kitson, M.
Program of Study:
A study of the relationship between vitamin D status and the severity and outcomes of chronic hepatitis C infection and nonalcoholic steatohepatitis. (PHD) 2014.
Supervisors:
Roberts, S (Main), Sievert, W (Associate), Visvanathan, K (Associate).
Student:
Knight, V.
Program of Study:
The role of PAR-1, PAR-2 and tissue factor in the development of Hepatic fibrosis. (PHD) 2014.
Supervisors:
Sievert, W (Joint-Co), Tipping, P (Joint).
Student:
Patella, S.
Program of Study:
ACTIVIN A AND FOLLISTATIN IN LIVER FIBROSIS AND CIRRHOSIS. (PHD) 2002.
Supervisors:
Sievert, W (Main), Phillips, D (Associate).
Student:
Pianko, S.
Program of Study:
HEPATITIS C INDUCED LIVER INJURY AND FACTORS INFLUENCING RESPONSE TO INTERFERON BASED THERAPY. (PHD) 2002.
Supervisors:
Holdsworth, S (Main), Sievert, W (Associate).
Student:
Ratnam, D.
Program of Study:
The role of the innate immune system in chronic hepatitis B infection. (PHD) 2013.
Supervisors:
Sievert, W (Main), Visvanathan, K (Associate).